金斯瑞生物科技(01548)：蓬勃根据与礼新医药科技的许可协议收到新付款

Core Viewpoint - Kingsray Biotechnology (01548) announced the receipt of approximately RMB 480 million (around USD 67.5 million, net of withholding tax) as the second payment under a revised licensing agreement related to an anti-PD-1 single-domain antibody [1] Group 1: Financial Impact - The payment is part of the licensing income associated with the anti-PD-1 single-domain antibody used in the development of the dual-specific antibody LM-299, which has received clinical research approval [1] - As of October 14, 2025, Kingsray has cumulatively received approximately RMB 2 billion (around USD 284 million, net of withholding tax) under the revised licensing agreement [1] Group 2: Strategic Use of Funds - The incoming funds will enhance Kingsray's cash reserves and will be utilized to support new molecular discovery and development [1]